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Abstract Several cinnamic acid esters were obtained via Fischer esterification of cinnamic acids 
derivatives with aliphatic alcohols. Cinnamic acids derivatives were synthesized via Knoevenagel 
reaction between substituted benzaldehydes and malonic acid in aqueous medium assisted by 
microwave heating. Structures of the products were elucidated by spectroscopic analysis. The 
synthesized compounds were evaluated for antileishmanial activity against L. panamensis amastigotes 
and cytotoxic activity against U-937 cells. The compounds 6, 10-12 and 18, were active against 
Leishmania parasite but toxic for mammalian cells. They are potential candidates for antileishmanial 
drug development.  
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Introduction 
 
Leishmaniasis is one of the world’s most neglected diseases, affecting largely the poorest of the poor, 
mainly in developing countries; 350 million people are considered at risk of contracting leishmaniasis, 
and some 2 million new cases occur yearly (Murray et al., 2005) and WHO has classified leishmaniasis 
as a category 1 disease, i.e. emerging and uncontrolled (http://www.who.int/topics/leishmaniasis/en/). 
This disease has symptoms from skin lesions to fatal systemic infection caused by protozoan parasites 
of the Leishmania species (Handman 1999). Recently, a dramatic increase in the number of cases of 
leishmaniasis has been observed in patients with compromised T-cell function, such as those infected 
with the human immunodeficiency virus (Wolday et al., 1999). Drugs currently in use as the antimony 
derivative glucantine, the bis-amidines, pentamidine and stilbamidine or the glycomacrolide 
amphotericin B, display high liver and heart toxicities, develop clinical resistance after a few weeks of 
treatment, and moderate and severe side effects (Desjeux et al., 2004; Ouellette et al., 2004; Barrett et 
al,. 2002; Croft et al., 2003; Faraut-Gambarelli et al., 1997; Olliaro et al,. 1993).  For these reasons it 
becomes necessary to discover new, more potent and selective agents for treating this increasing 
parasitosis.  
 
Caffeic acid (1), 3,4-dihydroxy cinnamic acid, and its esters derivatives exhibit a broad spectrum of 
biological activities, including anti-inflammatory (Jayaprakasam et al., 2006; Da Cunha et al., 2004), 
antimicrobial (Almajano et al., 2007; Noriaki et al., 2005; King et al.,1999; Valenta et al., 1998; 
Bowles et al., 1994) antioxidant (Hung et al., 2005; Noriaki et al., 2005; Kikuzaki et al,. 2002; Son et 
al., 2002; Rajan et al., 2001) and anticarcinogenic  effects (De et. al. 2011). Besides, some studies 
showed high leishmanicidal activity for these compounds (IC50 4.4 nM to caffeic acid (Radtke et al., 
2003) and 2.0, 10 and 1.8 μM to 2, 3 and 4 esters (fig. 1) (Cabanillas et al., 2010)). In the search of new 
therapeutic alternatives for the treatment of Leishmaniasis several cinnamic acid esters analogues were 
synthesized and their cytotoxic and leishmanicidal activities were determined. 
 
 
Fig. 1 Caffeic acid and its esters derivatives 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
Chemistry 
 
Cinnamic acid esters were obtained via Knoevenagel condensation in water under microwave heating 
(Gupta et al., 2007). These compounds were dissolved in thionyl chloride; the solution was stirred and 
refluxed by two hours. After evaporation, the acid chloride was added to a solution of cetyl alcohol in 
dichloromethane. Following evaporation and purification by column chromatography a total of six 
compounds were obtained. The cetyl alcohol was change by dodecyl alcohol or stearyl alcohol 
(Narasimhan et al., 2004). 3,4-dimethoxycinnamic acid was dissolved in methanol, propanol, 
pentanol, hexanol and octanol; acetyl chloride was added and the solution was stirred under reflux to 
complete the reaction. Following evaporation and purification by column chromatography a total of 
five compounds were obtained (De Campos et al., 2009). Compounds 17 and 18 were similarly 
obtained by starting from cinnamic and caffeic acid, respectively. Compound 16 was obtained by 
catalytic hydrogenation of compound 15 (Cardona et al., 2006) (scheme 1).  
 
 
 
 
Scheme 1. Synthetic pathway to cinnamic acid esters derivatives 
 
 
 
 
 
 
 
 
Antileishmanial Activity 
 
The leishmanicidal activity and cytotoxicity of the synthesized compounds as well as amphotericin B, 
used as control drug, were evaluated following the method previously reported in the literature (Varela 
et al., 2009; Robledo et al., 2005; Weninger et al., 2001; Robledo et al., 1999). The results were 
reported as EC50 and LC50 values of compounds and are shown in the tables 1 and 2. 
 
Table 1. In vitro leishmanicidal activity against axenic amastigotes of L. panamensis and toxicity of 
Cinnamic acid esters. 
 
 
Compound 
 
 
 
Cytotoxicity  
U937 cells 
 
LC50 (µg/ml)
a
 
Leishmanicidal 
Activity 
 
EC50(µg/ml)
b
 
SI
c
 
    
5  162.6 + 49.6 55.0+ 14.7 3.0 
6  85.3 + 17.5 33.0 + 0.2 2.6 
7 49.8 + 6.3 38.1+ 9.7 1.3 
8  54.7 + 7.7 60.0 + 4.0 0.9 
9  79.9 + 5.5  >100.0 <0.8 
10  49.7 + 18.1 59.0 + 1.9 0.8 
11 28.5 + 1.9 108.2 + 1.5 0.3 
12 69.1 + 6.7 55.4 + 2.0 1.2 
13 >200.0 >100.0 <2.0 
14 >200.0 >100.0 <2.0 
15 >200.0 >100.0 <2.0 
16 >200.0 >100.0 <2.0 
17 >200.0 >100.0 <2.0 
18 9.9 + 1.7 2.3 + 0.5
 
4.3 
Amphotericin B  29.6 + 4.7 0.05 + 0.01 592 
 
 
aLC50 : Lethal Concentration 50 
bEC50 : Effective Concentration 50;  
c SI: selectivity index: LC50 / EC50;  
d Cytotoxicity: LC50 <100 µg/ml; No Cytoxicity: LC50 >200 µg/ml; Active: EC50 <50 µg/ml; Moderately Active: EC50<100 µg/ml; No Active: EC50 >100 µg/ml 
 
According to the results shown in the table 1, only compounds 5, 6, 7, 8, 10, 12 and 18 showed activity 
against axenic amastigotes of L. panamensis with EC50 lower than 100 µg/ml. The most active 
compound was 18 (EC50 = 2.3 µg/ml) followed by 6 and 7 exhibiting EC50 values of 33.0 and 38.1 
g/ml, respectively. Compounds 5, 8, 10 and 12 showed a moderate leishmanicidal activity with an 
EC50 ranging between 55.0 and 60.0 µg/ml. On the other hand, a high toxicity activity was measured 
for compounds 6 to 12 and 18, with a LC50 < 100 µg/ml. The lower toxic activity was obtained with the 
compound 5 (EC50 = 162.6 µg/ml). No leishmanicidal activity and toxicity were detected for the 
compounds 13 to 17 (EC50 values higher than 100 µg/ml and LC50 higher than 200 µg/ml, 
respectively).  The best selectivity index was observed for compounds 18, 5 and 6 with values of 4.3, 
3.0 and 2.6, respectively. Compound 18 is structurally similar to the compound 4 reported by 
Cabanillas et al. (2010). Although the EC50 and LC50 values reported previously for compound 4 were 
slightly different, (EC50 = 0.55 µg/mL and LC50 3.9 µg/mL), both compounds are cytotoxic and highly 
active against Leishmania parasites. Differences in the Leishmania species and cell type used in the 
assays could explain the different results obtained with compounds 18 and 4. Thus, compound 4 was 
tested against axenic amastigotes of L. amazonensis and murine peritoneal macrophages (Cabanillas et 
al., 2010) whereas compound 18 was tested in this report against axenic amastigotes of L. panamensis 
and human macrophages. 
 
Structure-activity relationship 
 
There is a relationship between the leishmanicidal activity and compounds structure. The smaller the  
alkyl chains the higher the selectivity index (5, 6 vs 7-12); the degree of oxygenation is essential for 
activity, primarily in positions 2, 3 and 4 (12 vs 13-17); hydroxyl groups increase both the activity and 
cytotoxicity (9 vs 18); The importance of the double bond is not conclusive since the compounds were 
inactive, which can be related to the degree of oxygenation (16 vs 17). However, if the action 
mechanism involves a Michael addition for nucleophilic amino acid residues, this would be crucial for 
the activity as has been reported for other α,β-unsaturated compounds such as lactones, chalcones and 
cumarins (De Fatima et al., 2006; Buck et al., 2003). 
 
 
Table 2. In vitro activity of Cinnamic acid esters against intracellular amastigotes of L. panamensis. 
 
 
 
Compound 
 
Leishmanicidal Activity 
 
EC50(µg/ml) 
SI 
6 60.2 + 1.2 2.6 
10 25.2 +  2.3 2.0 
11 18.3 +  3.3 1.6 
12 26.5 +  2.0 2.7 
18 3.2 +  0.8 3.1 
Amphotericin B 0.06 +  0.01 592 
 
The leishmanicidal activity against the intracellular forms of Leishmania parasites was also measured 
for all compounds. Only the compounds 6, 10-12 and 18 were active (table 2). The most active 
compounds were 18 and 11 with EC50 of 3.2 and 18.3 µg/ml, respectively. The compound 6 had the 
lowest activity with EC50 60.2 µg/ml. The best SI was observed for compounds 18, 12 and 6 with 
values of 3.1, 2.7 and 2.6, respectively.  
 
Overall, the compounds 6, 10, 12 and 18 were apparently the most active compounds showing activity 
against both axenic and intracellular amastigotes of L. panamensis, while the compounds 5, 7 and 8 
showed activity only on the axenic form of this Leishamania species.  
 
 
Conclusion 
The design, synthesis, and antileishmanial screening of fourteen cinnamic acid esters was reported. 
Several of the reported compounds have potential as leishmanicidal drugs, as determined by both the 
leishmanicidal activity and the cytotoxicity. The compounds 6, 10-12 and 18, active against 
Leishmania parasite but toxic for mammalian cells, are potential candidates for antileishmanial drug 
development. However, more studies on toxicity using other cell lines are needed in order to 
discriminate whether the toxicity shown by these compounds is against tumor or non-tumor cells.  
Experimental procedures 
 Chemistry 
 
IR spectra were recorded on a Perkin-Elmer Spectrum RX I FT-IR system in a KBr disk. 
1
H NMR and 
13
C NMR spectra were recorded on Varian Unity 500 MHz spectrometer using CDCl3 as solvent and 
TMS as an internal standard. The chemical shifts are expressed in δ ppm. High resolution mass spectra 
were run by the electron impact mode (EIMS, 70 eV) on VG AutoSpec spectrometer. Silica gel 60 
(Merck 0.063-0.200 mesh) was used for column chromatography, and precoated silica gel plates 
(Merck 60 F254 0.2 mm) were used for TLC.  
 
Synthesis of cinnamic acid esters (5-9) 
 
Cinnamic acid (10 mmol), acetyl chloride (0.5 mmol), and the alcohol (50 ml), were placed in a 250 ml 
3-neck round- bottom flask equipped with a magnetic stirring bar. The mixture was stirred, heated to 
reflux for a period of 4 hours. The reaction mixture was concentrated on a rotatory evaporator, and the 
residue was purified by chromatographic column over silica gel eluted with a mixture hexane-ethyl 
acetate at different ratios to obtain the cinnamic acid esters in yield between 75-85%. 
 
 
Synthesis of cinnamic acid esters (10-16) 
 
Cinnamic acid (10 mmol) and thionyl chloride (10 ml) were placed in a 50 ml 3-neck round-bottom 
flask equipped with a magnetic stirring bar. The mixture was stirred, heated to reflux for a period of 4 
hours. The reaction mixture was concentrated on a rotatory evaporator, and the residue was added to a 
solution of cetyl alcohol (dodecyl or estearyl alcohol) in dichloromethane and the mixture was stirred 
and monitored by thin layer chromatography. The reaction was complete after about 4 hours. The 
mixture was transferred to a separatory funnel and then quenched by addition of a solution of 20 ml of 
potassium carbonate; the organic layer was washed with water, separated, dried on anhydrous sodium 
sulfate, filtered and concentrated under reduced pressure. The residue was chromatographed over silica 
gel (hexane-ethyl acetate, different ratios) to obtain the cinnamic acid esters in yield between 70-85%. 
 
 
Methyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (5) 
Yield 74%; yellow pale oil; IR (KBr, cm
-1
): ν max  2945 (C-H), 1700 (C=O), 1627 (C=C), 1510 
(C=CAr), 1270 (C-O-C), 1178 ((C=O)-O), 857 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 3.78 (3H, s, 
OCH3), 3.90 (6H, s, OCH3), 6.30 (1H, d, J = 15.9 Hz, –CO–CH=), 6.86 (1H, d, J = 8.0 Hz, Ar-H), 7.04 
(1H, d, J = 1.6 Hz, Ar–H), 7.10 (1H, dd, J = 8.0, 1.6 Hz, Ar–H), 7.63 (1H, d, J = 15.9 Hz, Ar-CH=C); 
13
C NMR (CDCl3, 125 MHz): δ 51.46 (OCH3), 55.83 (OCH3), 55.91 (OCH3), 109.50, 110.88, 115.51 
(=C-CO-),122.57, 127.38, 144.70 (Ar-C=), 149.18, 151.09, 167.40 (C = O).  MS: m/z 223.0972 (M + 
1).  
 
Propyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (6) 
Yield 70%; yellow pale oil; IR (KBr, cm
-1
): ν max  2967 (C-H), 1706 (C=O), 1635 (C=C), 1513 
(C=CAr), 1260 (C-O-C), 1177 ((C=O)-O), 808 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.97 (3H, t, J = 
7.4 Hz), 1.70 (2H, m), 3.88 (6H, s, OCH3), 4.13 (2H, t, J = 6.9 Hz), 6.29 (1H, d, J = 16.0 Hz, –CO–
CH=), 6.83 (1H, d, J = 8.3 Hz, Ar-H), 7.03 (1H, d, J = 1.8 Hz, Ar–H), 7.07 (1H, dd, J = 8.3, 1.6 Hz, 
Ar–H), 7.60 (1H, d, J = 16.0 Hz, Ar-CH=C);  13C NMR (CDCl3, 125 MHz): δ 10.37 (CH3), 22.02 
(CH2), 55.79 (OCH3), 55.86 (OCH3), 65.94 (-OCH2-), 109.59, 110.98, 115.86 (=C-CO-), 122.44, 
127.35, 144.37 (Ar-C=), 149.10, 150.95, 167.15 (C = O).  MS: m/z 251.1283 (M + 1).  
 Pentyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (7) 
Yield 85%; yellow pale oil; IR (KBr, cm
-1
): ν max  2958 (C-H), 1706 (C=O), 1635 (C=C), 1513 
(C=CAr), 1259 (C-O-C), 1160 ((C=O)-O), 807 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.92 (3H, t, J = 
7.3 Hz), 1.37 (4H, m), 1.70 (2H, m), 3.90 (6H, s, OCH3), 4.19 (2H, t, J = 6.8 Hz), 6.30 (1H, d, J = 16.0 
Hz, –CO–CH=), 6.85 (1H, d, J = 8.4 Hz, Ar-H), 7.05 (1H, d, J = 1.6 Hz, Ar–H), 7.09 (1H, dd, J = 8.4, 
1.6 Hz, Ar–H), 7.61 (1H, d, J = 16.0 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 13.79 (CH3), 
22.28 (CH2), 27.93 (CH2), 28.35 (CH2), 55.80 (OCH3), 55.87 (OCH3), 65.31 (-OCH2-), 109.55, 
110.06, 115.78 (=C-CO-), 122.37, 127.29, 144.25 (Ar-C=), 149.12, 151.01, 167.24 (C = O).  MS: m/z 
279.1596 (M + 1).  
 
Hexyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (8) 
Yield 83%; yellow pale oil; IR (KBr, cm
-1
): ν max  2957 (C-H), 1704 (C=O), 1600 (C=C), 1512 
(C=CAr), 1270 (C-O-C), 1173 ((C=O)-O), 808 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.91 (3H, t, J = 
7.0 Hz), 1.33 (4H, m), 1.41 (2H, m), 1.70 (2H, m), 3.91 (6H, s, OCH3), 4.19 (2H, t, J = 6.8 Hz), 6.31 
(1H, d, J = 15.9 Hz, –CO–CH=), 6.86 (1H, d, J = 8.2 Hz, Ar-H), 7.06 (1H, d, J = 1.8 Hz, Ar–H), 7.10 
(1H, dd, J = 8.2, 1.8 Hz, Ar–H), 7.62 (1H, d, J = 15.9 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 
13.85 (CH3), 22.43 (CH2), 22.59 (CH2), 28.74 (CH2), 31.46 (CH2), 55.84 (OCH3), 55.91 (OCH3), 64.76 
(-OCH2-), 109.56, 110.92, 115.97 (=C-CO-), 122.44, 127.33, 144.35 (Ar-C=), 149.07, 151.03, 167.07 
(C = O).  MS: m/z 293.1753 (M + 1).  
 
Octyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (9) 
Yield 80%; yellow pale oil; IR (KBr, cm
-1
): ν max  2956 (C-H), 1718 (C=O), 1633 (C=C), 1514 
(C=CAr), 1271 (C-O-C), 1176 ((C=O)-O), 802 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.81 (3H, t, J = 
6.6 Hz), 1.09-1.38 (10H, m), 1.61 (2H, m), 3.84 (6H, s, OCH3), 4.12 (2H, t, J = 6.7 Hz), 6.24 (1H, d, J 
= 16.6 Hz, –CO–CH=), 6.79 (1H, d, J = 8.4 Hz, Ar-H), 6.99 (1H, d, J = 1.3 Hz, Ar–H), 7.03 (1H, dd, J 
= 8.4, 1.3 Hz, Ar–H), 7.55 (1H, d, J = 16.6 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 14.52 
(CH3), 23.09 (CH2), 26.41 (CH2), 29.15 (CH2), 29.61 (2CH2), 32.20 (CH2), 56.27 (OCH3), 56.36 
(OCH3), 65.21 (-OCH2-), 109.88, 111.39, 112.69 (3CH), 116.29 (=C-CO-), 123.01, 144.95 (Ar-C=), 
167.68 (C = O).  MS: m/z   321.2023 (M + 1).  
 
 
Dodecyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (10) 
Yield 75%; M.p. 55-58 °C; IR (KBr, cm
-1
): ν max  2939 (C-H), 1697 (C=O), 1625 (C=C), 1512 (C=CAr), 
1251 (C-O-C), 1161 ((C=O)-O), 813 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.85 (3H, t, J = 6.9 Hz), 
1.15-1.35 (18H, m), 1.53 (2H, m), 3.61(2H, t, J = 6.67 Hz), 3.88 (6H, s, OCH3), 6.28 (1H, d, J = 16.4 
Hz, –CO–CH=), 6.84 (1H, d, J = 8.3 Hz, Ar-H), 7.02 (1H, d, J = 1.1 Hz, Ar–H), 7.08 (1H, dd, J = 8.3, 
1.1 Hz, Ar–H), 7.61 (1H, d, J = 16.4 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 14.65 (CH3), 
23.06 (CH2), 26.14 (CH2), 29.75-32.02 (6CH2), 32.28 (CH2), 33.27 (CH2), 56.28 (OCH3), 56.36 
(OCH3), 63.45 (-OCH2-), 109.86, 111.39, 113.34, 115.85 (=C-CO-), 122.88, 125.87, 137.42, 145.22 
(Ar-C=), 179.05 (C = O).  MS: m/z 377.2632 (M + 1).  
 
Hexadecyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (11) 
Yield 87%; M.p. 48-50 °C; IR (KBr, cm
-1
): ν max  2918 (C-H), 1719 (C=O), 1635 (C=C), 1500 (C=CAr), 
1271 (C-O-C), 1180 ((C=O)-O), 802 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.89 (3H, t, J = 7.1 Hz), 
1.15-1.47 (26H, m), 1.70 (2H, m), 3.91 (6H, s, OCH3), 4.20 (2H, t, J = 6.74 Hz), 6.31 (1H, d, J = 16.0 
Hz, –CO–CH=), 6.87 (1H, d, J = 8.3 Hz, Ar-H), 7.06 (1H, d, J = 1.6 Hz, Ar–H), 7.11 (1H, dd, J = 8.3, 
1.6 Hz, Ar–H), 7.63 (1H, d, J = 16.0 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 14.08 (CH3), 
22.64 (CH2), 25.70 (CH2), 28.18-29.85 (10CH2), 31.91(CH2), 32.79 (CH2), 55.84 (OCH3), 55.93 
(OCH3), 64.59 (-OCH2-), 109.60, 110.90, 116.02 (=C-CO-), 122.39, 127.45, 144.37 (Ar-C=), 150.95, 
151.03, 167.14 (C = O).  MS: m/z 433.3318 (M + 1).  
 
Octadecyl (2E)-3-(3,4-dimethoxyphenyl)prop-2-enoate (12) 
Yield 70%; M.p. 154-158 °C; IR (KBr, cm
-1
): ν max  2915 (C-H), 1708 (C=O), 1620 (C=C), 1506 
(C=CAr), 1274 (C-O-C), 1163 ((C=O)-O), 811 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.87 (3H, t, J = 
7.1 Hz), 1.18-1.39 (30H, m), 1.55 (2H, m), 3.62 (2H, t, J = 6.6 Hz), 3.92 (6H, s, OCH3), 6.38 (1H, d, J 
= 16.0 Hz, –CO–CH=), 6.88 (1H, d, J = 8.3 Hz, Ar-H), 7.07 (1H, d, J = 1.8 Hz, Ar–H), 7.15 (1H, dd, J 
= 8.3, 1.8 Hz, Ar–H), 7.78 (1H, d, J = 16.0 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 14.06 
(CH3), 22.60 (CH2), 25.70 (CH2), 29.30 (CH2), 29.40-29.80 (11CH2), 31.89 (CH2), 32.77 (CH2), 55.90 
(OCH3), 55.98 (OCH3), 63.03 (-OCH2-), 109.96, 111.08, 114.35 (=C-CO-), 123.55, 126.74, 148.47 
(Ar-C=), 149.33, 151.95, 162.84 (C = O).  MS: m/z 461.3631 (M + 1).  
 
 
Hexadecyl (2E)-3-(2,3-dimethoxyphenyl)prop-2-enoate (13)  
Yield 60%; M.p. 41-43 °C; IR (KBr, cm
-1
): ν max  2920 (C-H), 1719 (C=O), 1635 (C=C), 1515 (C=CAr), 
1270 (C-O-C), 1180 ((C=O)-O), 802 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.89 (3H, t, J = 7.1Hz), 
1.13-1.50 (26H, m), 1.72 (2H, m), 3.87 (3H, s, OCH3), 3.89 (3H, s, OCH3), 4.21 (2H, t, J = 6.7 Hz), 
6.49 (1H, d, J = 16.2 Hz, –CO–CH=), 6.94 (1H, d, J = 8.0 Hz, Ar-H), 7.06 (1H, t, J = 8.0 Hz, Ar–H), 
7.16 (1H, d, J = 8.0 Hz, Ar–H), 8.00 (1H, d, J = 16.2 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 
14.04 (CH3), 22.68 (CH2), 25.95 (CH2), 28.74 (CH2), 29.04-29.90 (10CH2), 31.86 (CH2), 55.88 
(OCH3), 61.26 (OCH3), 64.66 (-OCH2-), 113.85 (=C-CO-), 119.21, 119.65, 124.11, 128.69, 139.29 
(Ar-C=), 148.50, 153.15, 167.19 (C = O).  MS: m/z 433.3318 (M + 1).  
 
 
Hexadecyl (2E)-3-(2,5-dimethoxyphenyl)prop-2-enoate (14) 
Yield 85%; M.p. 63-65 °C; IR (KBr, cm
-1
): ν max  2918 (C-H), 1710 (C=O), 1630 (C=C), 1495 (C=CAr), 
1219 (C-O-C), 1177 ((C=O)-O), 802 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.89 (3H, t, J = 7.0 Hz), 
1.22-1.44 (26H, m), 1.72 (2H, m), 3.80 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.20 (2H, t, J = 6.81 Hz), 
6.50 (1H, d, J = 16.2 Hz, –CO–CH=), 6.85 (1H, d, J = 9.0 Hz, Ar-H), 6.92 (1H, dd, J = 9.0, 3.0 Hz), 
7.06 (1H, d, J = 3.0 Hz, Ar–H), 7.97 (1H, d, J = 16.2 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 MHz): δ 
14.08 (CH3), 22.68 (CH2), 25.96 (CH2), 28.77 (CH2), 29.17-29.97 (10CH2), 31.90 (CH2), 55.09 
(OCH3), 55.77 (OCH3), 64.56 (-OCH2-), 112.46, 113.24, 116.99, 119.04, 124.07 (=C-CO-), 139.67 
(Ar-C=), 152.77, 153.56, 167.37 (C = O).  MS: m/z 433.3318 (M + 1).  
 
Hexadecyl (2E)-3-(4-methoxyphenyl)prop-2-enoate (15) 
Yield 78%; M.p. 50-55 °C; IR (KBr, cm
-1
): ν max  2915 (C-H), 1707 (C=O), 1638 (C=C), 1517 (C=CAr), 
1268 (C-O-C), 1182 ((C=O)-O), 826 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.89 (3H, t, J = 7.1 Hz), 
1.19-1.46 (26H, m), 1.70 (2H, m), 3.84 (3H, s, OCH3), 4.20 (2H, t, J = 6.9 Hz), 6.32 (1H, d, J = 16.0 
Hz, –CO–CH=), 6.92 (2H, d, J = 8.7 Hz, Ar-H), 7.48 (2H, d, J = 8.7 Hz, Ar–H), 7.64 (1H, d, J = 16.0 
Hz, Ar-CH=C); 
13
C NMR (CDCl3, 125 MHz): δ 14.06 (CH3), 22.64 (CH2), 25.97 (CH2), 28.75 (CH2), 
29.20-29.82 (10CH2), 31.89 (CH2), 55.32 (OCH3), 64.58 (-OCH2-), 114.24, 115.79 (=C-CO-), 127.24, 
129.59, 144.11 (Ar-C=), 161.31, 167.33 (C = O).  MS: m/z 403.3212 (M + 1).  
 
Hexadecyl 3-(4-methoxyphenyl)propanoate (16) 
Yield 70%; yellow pale oil; IR (KBr, cm
-1
): ν max  2929 (C-H), 1735 (C=O), 1515 (C=CAr), 1247 (C-O-
C), 1175 ((C=O)-O), 835 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.90 (3H, t, J = 7.1Hz), 1.23-1.35 
(26H, m), 1.60 (2H, m), 2.60 (2H, t, J = 7.8), 2.90, (2H, t, J = 7.8), 3.79 (3H, s, OCH3), 4.07 (2H, t, J = 
7.1 Hz), 6.83 (2H, d, J = 8.3 Hz, Ar-H), 7.13 (2H, d, J = 8.3 Hz, Ar–H). 13C NMR (CDCl3, 125 MHz): 
δ 14.10 (CH3), 22.60 (CH2), 25.87 (CH2), 28.60 (CH2), 29.01-30.45 (11CH2), 31.94 (CH2), 36.16 
(CH2), 55.14 (OCH3), 64.54 (-OCH2-), 113.83,   129.18, 132.32, 158.04, 172.97 (C = O).  MS: m/z 
405.3369 (M + 1).  
 
Hexadecyl (2E)-3-phenylprop-2-enoate (17) 
Yield 94%; M.p. 35-36 °C; IR (KBr, cm
-1
): ν max  2952 (C-H), 1714 (C=O), 1640 (C=C), 1475 (C=CAr), 
1177 ((C=O)-O), 801 (C-HAr); 
1
H NMR (CDCl3, 500 MHz): δ 0.89 (3H, t, J = 7.0 Hz), 1.19-1.48 (26H, 
m), 1.72 (2H, m), 4.21 (2H, t, J = 6.8 Hz), 6.35 (1H, d, J = 16.0 Hz, –CO–CH=), 7.39 (3H, m, Ar–H), 
7.53 (2H, dd, J = 7.0, 2.2 Hz, Ar–H), 7.69 (1H, d, J = 16.0 Hz, Ar-CH=C); 13C NMR (CDCl3, 125 
MHz): δ 14.06 (CH3), 22.66 (CH2), 26.01 (CH2), 28.72 (CH2), 29.22-29.91 (10CH2), 31.89 (CH2), 
64.66 (-OCH2-), 118.32 (=C-CO-), 127.97, 128.82, 130.10, 134.45, 144.47 (Ar-C=), 167 (C = O).  MS: 
m/z 373.3107 (M + 1).  
 
Octyl 3-(3,4-dihydroxyphenyl)prop-2-enoate (18) 
 
Yield 72%; M.p. 101-104 °C; IR (KBr, cm
-1
): ν max  3318 (OH), 2920 (C-H), 1683 (C=O), 1604 (C=C), 
1442 (C=CAr), 1282 (C-O-C), 1178 ((C=O)-O), 815 (C-HAr); 
1
H NMR (DMSO-D6, 500 MHz): δ 0.79 
(3H, t, J = 6.5 Hz), 1.03-1.31 (10H, m), 1.53 (2H, m), 4.01 (2H, t, J = 6.0 Hz), 4.43 (2H, m, OH), 6.17 
(1H, d, J = 15.9 Hz, –CO–CH=), 6.75 (1H, d, J = 8.2 Hz, Ar-H), 6.83 (1H, d, J = 8.2 Hz, Ar–H), 7.02 
(1H, s, Ar–H), 7.42 (1H, d, J = 15.9 Hz, Ar-CH=C); 13C NMR (DMSO-D6, 125 MHz): δ 13.65 (CH3), 
22.35 (CH2), 25.73 (CH2), 28.50 (CH2), 28.98 (CH2), 31.41 (CH2), 45.96 (CH2), 63.98 (-OCH2-), 
111.65, 121.61 (=C-CO-), 125.93 (2C), 145.21 (2C), 148.20 (Ar-C=C), 167.68, 167.01 (C = O). MS: 
m/z   293.1732 (M + 1).  
 
 
 
Biological activity assays 
The compounds were subjected to in vitro leishmanicidal activity on amastigotes of L. panamensis and 
cytotoxic activity on mammalian cells.  
 
 
In vitro cytotoxic activity in mammalian cells 
 
The cytotoxic activity of the compounds was assessed based on the viability of the human 
promonocytic cell line U937 (ATCC CRL-1593.2
TM
) evaluated by the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) method as described by Robledo et al. (2005). In brief, cells were 
grown in 96-well cell-culture dishes at a concentration of 100,000 cells/ml in RPMI-1640 
supplemented with 10% FBS and the corresponding concentrations of the compounds, starting at 200 
lg/ml in duplicate. The cells were incubated at 37ºC with 5% CO2 for 72 h in the presence of the 
compounds, and then the effect was determined using MTT assay, incubating at 37ºC for 3 h. The 
effect of the compounds was determined by measuring the activity of the mitochondrial dehydrogenase 
by adding 10 ll/well of MTT solution (0.5 mg/ml) and incubating at 37 ºC for 3 h. The reaction was 
stopped by adding a 50% isopropanol solution with 10% sodium dodecyl sulfate for 30 min. Cell 
viability was determined based on the quantity of formazan produced, which was measured at 570 nm 
in a Bio-Rad ELISA. Cultured cells in the absence of extracts were used as viability controls; 
Amphotericin B was used as cytotoxicity control. The results are expressed as the Lethal Concentration 
50 (LC50) calculated by the Probit method (Finney, 1971). 
 
In vitro leishmanicidal activity on axenic and intracellular amastigotes 
 Axenic and intracellular amastigotes of GFP-transfected L. (V.) panamensis strain 
(MHOM/CO/87/UA140epirGFP) were used for the in vitro testing of leishmanicidal activity of the 
cinnamic acid esters derivatives. 
 
 
Activity against axenic amastigotes 
 
The respective ability of the cinnamic acid esters to kill axenic amastigotes of L. (V.) panamensis was 
determined based on the viability of the parasites evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) method as described previously (Taylor et al., 2010). In short, 
parasites were cultivated in Schneider’s medium pH 5.4 supplemented with 20% heat inactivated FBS 
for 3 days at 32ºC. Afterward, they were harvested, washed, and resuspended at 2 x 10
6
 axenic 
amastigotes/ml in fresh medium. Each well of a 96-well plate was seeded with 100 µl of each parasite 
suspension (in duplicate), and 100 µl of each concentration of the test compound was added, starting at 
100 µg/ml. Plates were incubated at 32ºC. After 72 h of incubation, the effect of drugs was determined 
by adding 10 µl/well of MTT and incubating at 32ºC for 3 h. The reaction was stopped, and the 
quantity of formazan produced was measured with a Bio-Rad ELISA reader set at 570 nm. Parasites 
cultivated in the absence of the compound but maintained under the same conditions were used as 
controls for growth and viability. Parasites cultivated in the presence of Amphotericin B were used as 
controls for leishmanicidal activity. 
 
Activity against intracellular amastigotes 
 
The effects of cinnamic acid esters against intracellular amastigotes of L. (V.) panamensis were 
evaluated by flow cytometry using the methodology described by Varela et al. (2009). In brief, U937 
cells were dispensed in 24-well plates at a concentration of 300,000 cells/well, which were treated with 
1 µM of Phorbol Myristate Acetate (PMA) for 48 h at 37ºC, after which they were infected with 
promastigotes of L. (V.) panamensis in stationary growth phase (day 5) in modified NNN medium, a 
proportion of 1:25 cell/parasite, after 3 h of incubation at 34ºC in 5% CO2 non-internalized parasites 
were washed, and incubated again at 34ºC and 5% CO2 to allow differentiation to amastigotes form. 
After 24 h of incubation, the compounds with the appropriate dilution, not exceeding the LC50, were 
added. Infected and treated cells were maintained at 34ºC and 5% CO2 for 72 h. The leishmanicidal 
effect was measured in a flow cytometer at 488 nm of excitation and 525 nm of emission, and 
determined as described by Varela et al. (2009). The results are expressed as the Effective 
Concentration 50 (EC50) calculated by the Probit statistical method. The data are the averages of three 
independent experiments conducted in duplicate. Infected but untreated cells were used as control of 
viability. In addition, infected cells exposed to Amphotericin B were used as leishmanicidal activity 
controls. The Selectivity Index (SI) was calculated by dividing the cytotoxic activity between the 
leishmanicidal activity (SI = LC50/EC50). 
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